text: OBJECTIVE: This randomized, double-blind study tested the hypothesis that << rofecoxib >>, a drug that specifically inhibits [[ cyclooxygenase 2 ]], would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).